

Na L

Position: Associate Professor

Faculty: State Key Laboratory of Quajr

professor, chemist, specializing in the isolation and structural elucidation of bioactive components and biomarkers using NMR and MS techniques. She has published over 50 research articles in a number of international journals including Journal of Hepatology, JAS, Analytical Chemistry, Journal of Medicinal Chemistry, Molecular Pharmaceutics, Journal of Mass Spectrometry, Analytica Chimica Acta, Journal of Natural Products and etc.

A a Q a a

1999.7 Ph. D. China Pharmaceutical University, Nanjing, Jiangsu Province, China

1994.7 B. Sc. West China University of Medical Sciences, Chengdu, Sichuan Province, China

W E

2018.7 – Present Associate Professor, State Key Laboratory for Quality Research in Chinese Medicine, Macau University of Science and Technology 222

MS

OPENING

1000

inside

patot
Zhe
Reacti
U
6) asBi
Y aZhen
u* atization
separation
main
ng
geted
mlogra
ma

WORLD'S

WORLD'S

43

CKT

8A

- alkaloids from *L* targeting DNA topoisomerase I. . . . **2016, 6**, 38284.
- 15) JJ Wu, N Lin, FY Li, GY Zhang, SG He, YF Zhu, RL Qu, N L , SQ Liu, LZ Feng, L Liu, ZQ Liu, LL Lu. Induction of P-glycoprotein expression and activity by Aconitum alkaloids: implication for clinical drug-drug interactions. . . . **2016, 6**, 25343.
 - 16) L Zhu, JQ Ruan, N L , PP Fu, Y Ye, G Lin. A novel ultra-performance liquid chromatography hyphenated with quadrupole time of flight mass spectrometry method for rapid estimation of total toxic retronecine-type of pyrrolizidine alkaloids in herbs without requiring corresponding standards. *F C* . **2016, 194**, 1320-1328.
 - 17) ZB Jiang, J Huang, C Xie, X Li, L Liu, J He, H Pan, L Huang, XX Fan, XJ Yao, Y Xie, N L , L Liu, JX He, EL Leung. Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations. . . . **2016, 36(1)**, 365-375.
 - 18) J Ruan, H Gao, N L , J Xue, J Chen, C Ke, Y Ye, PP Fu, J Zheng, J Wang, G Lin. Blood pyrrole-protein adducts - A biomarker of pyrrolizidine alkaloid-induced liver injury in humans. *J E . . H C E . C . E .* . **2015, 33**, 404-421.
 - 19) YH Li, WCS Tai, JY Xue, WY Wong, C Lu, JQ Ruan, N L , TF Wan, WY Chan, WLW Hsiao, and G Lin. Proteomic Study of Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstruction Syndrome in Rats. *C . . .* . **2015, 28**, 1715-1727.
 - 20) H Gao, JQ Ruan, J Chen, N L , CQ Ke, Y Ye, G Lin, JY Wang. Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome. *D D , D* . **2015, 9**, 4861-4868.
 - 21) WY Gu, N L *, ELH Leung, H Zhou, XJ Yao, L Liu, JL Wu*. Rapid identification of new minor chemical constituents from *Smilacis Glabrae Rhizoma* by combined use of UHPLC-Q-TOF-MS, preparative HPLC and UHPLC-SPE-NMR-MS techniques. . *A* . **2015, 26**, 428-435.
 - 22) WY Gu, N L *, ELH Leung, H Zhou, GA Luo, L Liu, JL Wu*. Metabolites software-assisted flavonoids hunting in plant using ultra-high performance liquid chromatography-quadrupole-time of flight mass spectrometry. *M* . **2015, 20**, 3955-3971.
 - 23) L Zhu, N L , JQ Ruan, PP Fu, ZZ Zhao, G Lin. Chemical diversity investigation of hepatotoxic pyrrolizidine alkaloids in *Qianliguang* () and related species by UHPLC-QTOF-MS. *J . C . M* . **2015, 1**, 1-11.
 - 24) XX Fan, N L , et al. Celastrol induces apoptosis in gefitinib-resistant non-small cell lung cancer cells via caspases-dependent pathways and Hsp90 client protein degradation.

- M* **2014**, *19*, 3508-3522.
- 25) JL Wu, EL Leung, H Zhou, L Liu*, N L *. Metabolite analysis of toosendanin by an ultra-high performance liquid chromatography-quadrupole-time of flight mass spectrometry technique. *M* **2013**, *18*, 12144-12153.
 - 26) YH Li, WL Kan, N L , G Lin. Assessment of pyrrolizidine alkaloid-induced toxicity in an in vitro screening model. *J. E* **2013**, *150*, 560-567.
 - 27) J Ruan, N L , et al. Characteristic ion clusters as determinants for the identification of pyrrolizidine alkaloid *N*-oxides in pyrrolizidine alkaloid-containing natural products using HPLC–MS analysis. *J. M* **2012**, *47*, 331-337.
 - 28) Q Liu, N L , et al. Cyclobutane derivatives as novel nonpeptidic small molecule agonists of glucagon-like peptide-1 receptor. *J. M . C* **2012**, *55*(1), 250-267.
 - 29) H Gao, N L , et al. Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids. *J. D . D* **2012**, *13*, 33-39.
 - 30) B Ma, S Chai, N L , et al. Reversal of P-glycoprotein-mediated multidrug resistance by a synthetic α -aminoxy peptidomimetic. *I . J.* **2012**, *424*, 33-39.
 - 31) B Ma, N L , G Lin. Importance of Metabolic Activation Study to the Safe Use of Chinese Herbal Medicines. *C . D M* **2012**, *13*, 652-658.
 - 32) G Lin,* JY Wang,* N L , et al. Hepatic sinusoidal obstruction syndrome associated with consumption of *G* *J. H* **2011**, *54*, 666-673.
 - 33) B Ma, HY Zha, N L , et al. Effect of structural modification of α -aminoxy peptides on their intestinal absorption and transport mechanism. *M* **2011**, *8*, 1073-1082.
 - 34) N L , Q Xia, J Ruan, et al. Hepatotoxicity and tumorigenicity induced by metabolic activation of pyrrolizidine alkaloids in herbs. *C . D M* **2011**, *12*, 823-834.